Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 1997

View Archived Issues

Potent and selective dopamine D3 ligands from ADIR

Kyowa Hakko discovers inhibitors of IL-1beta production

ET antagonists claimed by Bristol-Myers Squibb

Roche describes endothelin antagonists

Antioxidant diester reported by Senju

Novel, irreversible HIV protease inhibitor disclosed by LG Chemical

Human PEP inhibitor isolated from microbial sources

Tokyo Tanabe developing oxytocin antagonist

Full 5-HT1A receptor antagonist described by Duphar

Synthesis and pharmacological profile of new antithrombotic pentasaccharide

Pharmacological profile of BMS-186716 characterized

Abelcet approved in Canada

Corvas to strengthen anticancer program with option to acquire Vascular Genomics

New immunoassay for DVT diagnosis

CoCensys reports on phase II trial with ganaxolone

Topical t-PA for the treatment of venous ulcers

Celtrix's SomatoKine enters phase II feasibility study for the treatment of burns

Injectable microsphere-encapsulated norethindrone is a safe and effective contraceptive

Edex cleared for erectile dysfunction in the U.S.

Nycomed and Amersham announce proposed merger

Sepracor submits first NDA for levalbuterol

Shire acquires distribution rights for Urispas from Recordati

Oncogene Science and Xenometrix alliance for drug discovery/lead optimization technologies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.